Evidence map›Paper›PMID 37463068›Full record

ArticleJournal of the American Society for Mass Spectrometry2023

Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors.

Min Ma, Fabao Liu, Hannah N Miles, Eui-Jun Kim, Lauren Fields, Wei Xu, Lingjun Li

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Role of PRMT1 and PRMT5 in Breast Cancer.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Min MaSchool of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
Fabao LiuMcArdle Laboratory for Cancer Research, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
Hannah N MilesSchool of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
Eui-Jun KimMcArdle Laboratory for Cancer Research, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0002-8475-5229
Lauren FieldsDepartment of Chemistry, University of Wisconsin─Madison, Madison, Wisconsin 53706, United States.ORCID 0000-0001-8155-642X
Wei XuMcArdle Laboratory for Cancer Research, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
Lingjun LiSchool of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0003-0056-3869
University of Wisconsin–Madison · US

Funding

Chemistry-Biology Interface Training ProgramT32GM008505 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLACKWELL, HELEN E. · 1993 to 2023
$9.8M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
Protein Arginine Methylation in Breast CancerR01CA236356 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Wei Xu · 2019 to 2026
$2.9M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Ctr9 as a Predictive Biomarker for EZH2 Inhibitor SensitivityR01CA268183 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Wei Xu · 2022 to 2026
$2.0M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
Acquisition of a High Resolution High Speed MALDI Mass Spectrometer for Biomedical Research at UW-MadisonS10OD025084 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$598k
NCI NIH HHS R01 CA236356NCI NIH HHS R01 CA268183NCRR NIH HHS S10 RR029531NIA NIH HHS R01 AG052324NIA NIH HHS R01 AG078794NIDDK NIH HHS R01 DK071801NIGMS NIH HHS T32 GM008505NIH HHS S10 OD025084NIH HHS S10 OD028473
6 · The paper itself

Abstract

Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is a prevalent post-translational modification (PTM) that regulates diverse cellular processes. Aberrant expression of type I PRMTs that catalyze asymmetric arginine dimethylation (ADMA) is often found in cancer, though little is known about the ADMA status of substrate proteins in tumors. Using LC-MS/MS along with pan-specific ADMA antibodies, we performed global mapping of ADMA in five patient-derived xenograft (PDX) tumors representing different subtypes of human breast cancer. In total, 403 methylated sites from 213 proteins were identified, including 322 novel sites when compared to the PhosphositesPlus database. Moreover, using peptide arrays

Indexed as

Breast NeoplasmsProteomeArginineChromatography, LiquidFemaleHumansNuclear ProteinsProtein-Arginine N-MethyltransferasesRepressor ProteinsTandem Mass SpectrometryArginineNuclear ProteinsPRMT1 protein, humanPRMT6 protein, humanProtein-Arginine N-MethyltransferasesProteomeRepressor Proteinsarginine methyltransferasesasymmetric arginine dimethylationbreast cancerimmunoaffinityliquid chromatography tandem-mass spectrometrypatient-derived xenograftpost-translational modification

Identifiers

PMID37463068
PMCPMC10726702
OpenAlexW4384662136

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.